SCHEMBL124385

SCHEMBL124385

N[C@@H](CCC(=O)OCc1ccccc1)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC15A1 P46059 2/20 0.55
LTA4H P09960 4/20 0.54
ALDH1A1 P00352 3/20 0.54
MAPK1 P28482 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
SLC1A1 P43005 4/20 0.52
SLC1A3 P43003 3/20 0.52
ALPI P09923 1/20 0.51
PKM P14618 1/20 0.51
PTGS1 P23219 1/20 0.51
XIAP P98170 1/20 0.51
SLC7A5 Q01650 1/20 0.51
SLC1A2 P43004 2/20 0.47
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
TDP1 Q9NUW8 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL432780 1.00 SLC15A1 (0.55) SLC15A1LTA4HALDH1A1MAPK1L3MBTL1
SCHEMBL4850398 1.00 SLC15A1 (0.55) SLC15A1LTA4HALDH1A1MAPK1L3MBTL1
Hydrochloric Acid SCHEMBL29398213 0.98 SLC15A1 (0.53) SLC15A1LTA4HALDH1A1MAPK1L3MBTL1
Urea SCHEMBL4473115 0.97 SLC15A1 (0.52) SLC15A1LTA4HALDH1A1MAPK1L3MBTL1
Glutamic Acid SCHEMBL7243656 0.95 SLC1A1 (0.53) SLC15A1LTA4HALDH1A1MAPK1L3MBTL1
Alanine SCHEMBL4410297 0.94 SLC15A1 (0.52) SLC15A1LTA4HALDH1A1MAPK1L3MBTL1
SCHEMBL8411886 0.94 LTA4H (0.50) SLC15A1LTA4HALDH1A1MAPK1L3MBTL1
Glutamic Acid SCHEMBL28192477 0.92 SLC1A1 (0.49) SLC15A1LTA4HALDH1A1MAPK1L3MBTL1
SCHEMBL28389656 0.92 SLC1A1 (0.49) SLC15A1LTA4HALDH1A1MAPK1L3MBTL1
SCHEMBL13764234 0.91 SLC15A1 (0.52) SLC15A1LTA4HALDH1A1MAPK1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1851 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4695257-A1 PROCESS FOR THE PREPARATION OF REMIMAZOLAM AND SALTS THEREOF Harman Finochem Limited (IN) 2026-02-18 EP claimed
US-20260027218-A1 STAR-SHAPED GRAFT COPOLYMERS POLYPEPTIDE THERAPEUTIC SOLUTIONS S L (ES) 2026-01-29 US claimed
EP-4674441-A1 RARE EARTH NANO FLUORESCENCE-NUCLEAR MEDICINE TUMOR TOMOGRAPHY-THERAPY INTEGRATED PREPARATION, PREPARING METHOD THEREFOR, AND USE METHOD AND USE THEREOF Zhongke Rare Earth Nanotechnology (Hebei) Co., Ltd (CN) 2026-01-07 EP claimed
US-12487218-B2 Polymer nanostructures, methods of making same, and uses thereof CORNELL UNIVERSITY (US) 2025-12-02 US claimed
US-20250208137-A1 COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES CAMBRIDGE ENTERPRISE LIMITED (GB) 2025-06-26 US claimed
CN-120136804-A Glutamic acid-N-carboxyl-cyclic anhydride monomer containing ethyl nitrate group, polymer thereof and application of glutamic acid-N-carboxyl-cyclic anhydride monomer serving as nitric oxide donor 武汉理工大学 2025-06-13 CN claimed
US-20250171495-A1 MUTLI-TARGETED SERINE PROTEASE INHIBITORS FOR TREATMENT OF CANCER AND VIRAL INFECTION WASHINGTON UNIVERSITY 2025-05-29 US claimed
EP-4532586-A1 STAR-SHAPED GRAFT COPOLYMERS Polypeptide Therapeutic Solutions, S.L. (ES) 2025-04-09 EP claimed
CN-119681258-A Hybrid gold nanoparticle and preparation method and application thereof 嘉庚创新实验室 2025-03-25 CN claimed
CN-119605880-A Processing technology of floating beam green tea 浮梁县天祥茶号有限公司 2025-03-14 CN claimed
EP-0362031-B1 COMPOUNDS ACTIVE AGAINST MALARIA OF THE TISSUES, AND PROCESS FOR THEIR PREPARATION LA REGION WALLONNE (BE) 1993-07-07 EP claimed
WO-1992018518-A1 NUCLEOSIDES AND OLIGONUCLEOSIDES WITH A PHOSPHATE-FREE INTERNUCLEOSIDE BACKBONE AND PROCESS FOR PREPARING THE SAME BAYLOR COLLEGE OF MEDICINE (US) 1992-10-29 WO claimed
US-5007930-A Coating a supplementation or replacement; dentistry, bone prosthetics THE DOW CHEMICAL COMPANY (US) 1991-04-16 US claimed
EP-0362031-A1 Compounds active against malaria of the tissues, and process for their preparation LA REGION WALLONNE (BE) 1990-04-04 EP claimed
EP-0213996-B1 RAMIFIED POLYMERS BASED ON LIPOPEPTIDES FORMING THERMOTROPIC AND LYOTROPIC LIQUID CRYSTALS, THEIR USE AND CORRESPONDING MONOMERS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 1989-09-06 EP claimed
US-4842604-A MOLDING AND IMPLANTING POROUS MATERIAL; POLYESTER OR AMINO ACID POLYMER THE DOW CHEMICAL COMPANY (US) 1989-06-27 US claimed
US-4698375-A POLYGLYCOLIC ACID, LATIC ACID, HYDROXYBUTYRATE, ALPHA-AMINO ACID THE DOW CHEMICAL COMPANY (US) 1987-10-06 US claimed
US-4636526-A Composites of unsintered calcium phosphates and synthetic biodegradable polymers useful as hard tissue prosthetics THE DOW CHEMICAL COMPANY (US) 1987-01-13 US claimed
US-4525495-A CONTAINING AMINO ACID POLYMER THE DOW CHEMICAL COMPANY (US) 1985-06-25 US claimed
US-3936469-A Process for preparing N-carboxylic anhydrides of amino acids KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JA) 1976-02-03 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171495-A1 MUTLI-TARGETED SERINE PROTEASE INHIBITORS FOR TREATMENT OF CANCER AND VIRAL INFECTION TMPRSS2, PRSS1, PRSS2 SLC15A1 1329/4885LTA4H 2097/4885ALDH1A1 2588/4885
US-20260027218-A1 STAR-SHAPED GRAFT COPOLYMERS RHOA, PCNA, HBZ SLC15A1 2709/4885LTA4H 4148/4885ALDH1A1 4727/4885
US-20250208137-A1 COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES F11, F2, F12 SLC15A1 4543/4885LTA4H 209/4885ALDH1A1 3232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.